Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal Methotrexate for CNS Prophylaxis in GTN 266 Gynaecology PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) 267 Gynaecology Two Day Etoposide CISplatin (EP) 16/02/2018 460 Gastrointestinal CISplatin 75mg/m2 and 5-Fluorouracil Chemoradiation -Herskovic Regimen 462 Sarcoma Pegylated Liposomal DOXOrubicin 20mg/m2 (CAELYX) 21 s 464 Skin/Melanoma Dacarbazine 10/02/2018 256 Gastrointestinal Nab-PACLitaxel (Abraxane ) and Gemcitabine 28 07/02/2018 201 Breast Trastuzumab (IV) Monotherapy 7 s 207 Gastrointestinal Cetuximab Monotherapy-7 s Head & Neck Cetuximab Monotherapy-7 s 246 Gynaecology Methotrexate 8 Charing Cross Regimen 247 Gynaecology DACTINomycin 248 Gynaecology EMA/CO 264 Gynaecology Etoposide CISplatin/Etoposide Methotrexate Actinomycin D (EP/EMA) 437 Genitourinary TICE -Autologous Conditioning Germ Cell Tumour Regimen 28/01/2018 243 Crizotinib Monotherapy 27/01/2018 243 Crizotinib Monotherapy 26/01/2018 243 Crizotinib Monotherapy 18/12/2017 355 Myeloma Dose Adjusted R-EPOCH CARBOplatin (AUC7) and Etoposide- Autologous 453 Genitourinary Conditioning Germ Cell Tumour Regimen CISplatin (50mg/m2) Etoposide (100mg/m2) and 456 Thoracic Radiotherapy (TRT) -28 11/12/2017 333 Genitourinary Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) -14 Days 338 Genitourinary Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) -28 Days 339 Vinorelbine and CISplatin -21 s 06/12/2017 102 Skin/Melanoma Vemurafenib Monotherapy
06/12/2017 271 CARBOplatin (AUC5) and Etoposide 100mg/m2-21 283 Gastrointestinal Gemcitabine (1000mg/m2) Monotherapy - 56 284 Gastrointestinal Gemcitabine (1000mg/m2) Monotherapy - 28 Gemcitabine (1000mg/m2) Monotherapy - 28 300 Genitourinary Bleomycin, Etoposide and CISplatin 301 Genitourinary Etoposide and CISplatin 20mg/m2 (EP) CISplatin (40mg/m2) Weekly with Radiotherapy 385 Genitourinary (RT) CISplatin (40mg/m2) Weekly with Radiotherapy Gynaecology (RT) CISplatin (40mg/m2) Weekly with Radiotherapy Head & Neck (RT) DOXOrubicin (25mg/m2/) and CISplatin 420 Sarcoma (100mg/m2) - 21 cycle 17/11/2017 398 Myeloma R-CODOX-M (Patients less than or equal to 65 years) 399 Myeloma R-IVAC (Patients less than or equal to 65 years) 403 Myeloma R-CODOX-M (Patients greater than 65 years) 404 Myeloma R-IVAC (Patients greater than 65 years) 450 Genitourinary 5-Fluorouracil and mitomycin Chemoradiation 451 Gastrointestinal 5-Fluorouracil (4 ) and mitomycin Chemoradiation 15/11/2017 228 Breast EriBULlin Monotherapy 265 Breast 5-Fluorouracil, epirubicin 100 and Cyclophosphamide (FEC 100) Fluorouracil, epirubicin 100 and Cyclophosphamide (FEC 100) 269 Breast 5-Fluorouracil, epirubicin 50 and Cyclophosphamide (FEC50) 278 Breast Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 followed by PACLitaxel (175) 14 (DD AC-T) 281 Gemcitabine (1250mg/m2) and CISplatin (75mg/m2) - 21 282 Genitourinary Gemcitabine (1000mg/m2) and CISplatin (70mg/m2) - 28
15/11/2017 306 Gynaecology Gemcitabine (1000mg/m2) and CARBOplatin (AUC 4) - 21 Gemcitabine + CARBOplatin (AUC 4) - 21s 310 Genitourinary Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) - 21 Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) - 21 383 Gastrointestinal Gemcitabine (1000mg/m2) and CISplatin (25mg/m2) - 21 02/11/2017 341 Gynaecology Olaparib Monotherapy 01/11/2017 236 Skin/Melanoma Vismodegib Monotherapy 424 Myeloma Obinutuzumab and Bendamustine -28 cycle 425 Myeloma Obinutuzumab Maintenance following O-Bendamustine therapy 26/10/2017 379 Neuro-oncology Procarbazine Lomustine and VinCRIStine (PCV) 23/10/2017 432 Breast DOXOrubicin, Cyclophosphamide (AC 60/600) 21 followed by weekly PACLitaxel (80) and weekly Trastuzumab (AC-TH) 433 Breast Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 followed by weekly PACLitaxel (80) and weekly Trastuzumab (AC-TH) 445 Genitourinary Pazopanib Sarcoma Pazopanib 446 Gastrointestinal Bevacizamab 5mg/kg and Modified FOLFOX-6-14 447 Gastrointestinal Panitumumab 6mg/kg and Modified FOLFOX-6 14 448 Gastrointestinal Panitumumab 6mg/kg and FOLFIRI 14 449 Gastrointestinal Bevacizumab 5mg/kg and FOLFIRI 14 s 09/10/2017 349 Genitourinary Nivolulmab Monotherapy Myeloma Nivolulmab Monotherapy Skin/Melanoma Nivolumab Monotherapy 431 Skin/Melanoma Nivolumab Ipilimumab Combination 06/10/2017 344 Gastrointestinal FLOT -14 02/10/2017 401 Alectinib Monotherapy 29/09/2017 261 Breast CARBOplatin (AUC4-6) Monotherapy-21 s Gynaecology CARBOplatin (AUC4-6) Monotherapy-21 s 27/09/2017 251 Breast CARBOplatin Monotherapy-28 s Gynaecology CARBOplatin (AUC4-6) Monotherapy-28 s
27/09/2017 252 Breast DOXOrubicin and Cyclophosphamide 20/09/2017 206 Breast Trastuzumab Emtansine (Kadcyla ) - 21 s 255 Myeloma Pixantrone 258 Breast DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 s 272 Breast Trastuzumab Subcutaneous 21 s- Metastatic Breast Carcinoma 277 Myeloma Siltuximab Monotherapy 279 CISplatin (75mg/m2) + Etoposide (100mg/m2) +Thoracic Radiotherapy (TRT) -21 280 CISplatin (75mg/m2) + Etoposide -21 285 Breast Trastuzumab SC 21 s-early Breast Cancer 286 Myeloma Obinutuzumab and Chlorambucil 11/09/2017 231 Leukaemia/BMT Decitabine Monotherapy AML (28 cycle) 296 Leukaemia/BMT Ibrutinib Therap (CLL/ Waldenstrom's Macroglobulinaemia) 08/09/2017 297 Myeloma Ibrutinib Therap (Mantly Cell Lymphoma) 28/07/2017 359 Leukaemia/BMT DA(60/100) 3+10: Course 1 Induction (AML-17) 360 Leukaemia/BMT DA (50/100) (3+8) Course 2 Induction (AML-17) 364 Leukaemia/BMT Intermediate Dose Cytarabine 365 Leukaemia/BMT High Dose Cytarabine 395 Myeloma (R**)-DHAP 397 Myeloma (R**)-ICE ((rituximab), Ifosfamide, CARBOplatin and Etoposide) 408 Myeloma BEAM Autologous Transplant Conditioning Protocol 429 Gastrointestinal epirubicin, Oxaliplatin and 5-FU (EOF) - 21 07/07/2017 422 Gastrointestinal CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m2) Weekly with Radiotherapy (RT) -5 weeks 423 Breast DOXOrubicin 50mg/m2/DOCEtaxel 75mg/m2(AT 50/75) - 21 cycle 427 Gastrointestinal Modified Roswell Park (Fluorouracil 500mg/m2 and Folinic Acid 50mg weekly x 6) Regimen 428 Gastrointestinal QUASAR (Modified) Fluorouracil(370mg/m2) and Folinic Acid (50mg) Weekly
07/07/2017 430 Breast Gemcitabine and CARBOplatin (AUC2) THERAPY - 21 s 03/07/2017 366 Leukaemia/BMT Tretinoin (ATRA)/Idarubicin (PETHEMA AIDA) Induction 01/07/2017 239 Gastrointestinal epirubicin, Oxaliplatin and Capecitabine (EOX) 240 Gastrointestinal epirubicin, CISplatin and 5-FU (ECF) 20/06/2017 259 Breast Oral Vinorelbine Monotherapy-7s Oral Vinorelbine Monotherapy-7s 260 Breast DOXOrubicin, Cyclophosphamide followed by weekly PACLitaxel DOXOrubicin, Cyclophosphamide followed by weekly PACLitaxel (AC-T) 262 Breast epirubicin 90 + Cyclophosphamide (EC90) 263 Breast epirubicin 75 + Cyclophosphamide (EC75) 30/05/2017 200 Breast Trastuzumab (IV) Monotherapy 21 s 202 Breast DOCEtaxel Monotherapy 100mg/m2 21 cycle 203 Genitourinary DOCEtaxel Monotherapy 75mg/m2 21 cycle DOCEtaxel Monotherapy 75mg/m2 21 cycle 211 Gastrointestinal Bevacizumab 5mg/kg - 14 s 212 Breast Bevacizumab 10mg/kg-14s Gastrointestinal Bevacizumab 10mg/kg-14s Genitourinary Bevacizumab 10mg/kg-14s Gynaecology Bevacizumab 10mg/kg-14s 214 Gastrointestinal Bevacizumab 7.5mg/kg-21s Bevacizumab 7.5mg/kg-21s 215 Breast Bevacizumab 15mg/kg - 21 s Gastrointestinal Bevacizumab 15mg/kg - 21 s Gynaecology Bevacizumab 15mg/kg - 21 s Bevacizumab 15mg/kg - 21 s 225 Gastrointestinal Panitumumab 6mg/kg 250 Breast DOCEtaxel /Cyclophosphamide (TC) -21 11/05/2017 417 Head & Neck Cetuximab (weekly), CISplatin 100mg/m2 and 5- FU 1000mg/m2/ - 21 cycle 418 Head & Neck Cetuximab (weekly), CARBOplatin AUC 5 and 5- FU 1000mg/m2/ - 21 cycle 419 Head & Neck CARBOplatin (AUC 2) Weekly with Radiotherapy (RT) 421 Gastrointestinal 5-Fluorouracil 225mg/m2/ and Radiotherapy (RT)-Continuous infusion 7
02/05/2017 416 Myeloma 05/04/2017 345 Myeloma Bortezomib, Lenalidomide and Dexamethasone (RVD) - 21 rituximab and Bendamustine 15/03/2017 295 Head & Neck Lenvatinib 409 Myeloma R-CHOP-14 s 08/03/2017 241 Leukaemia/BMT 293 Myeloma 307 Myeloma 393 Myeloma 396 Myeloma Fludarabine, Cyclophosphamide and rituximab (FC IV+R) (*rituximab), Cyclophosphamide VinCRIStine and Prednisolone (*R)-CVP) 21 s (R*)-CHOP 21 s Nordic Protocol CHOEP 21 s Fludarabine, Cyclophosphamide and rituximab (FC Oral+R) 410 Leukaemia/BMT 01/03/2017 100 Sarcoma Mifamurtide 101 Genitourinary Cabazitaxel and Prednisolone 209 Gastrointestinal Modified FOLFOX-6-14 210 Gastrointestinal FOLFOX-4-14 219 Erlotinib Monotherapy 226 Breast PACLitaxel Monotherapy 80mg/m2 7 Gastrointestinal PACLitaxel Monotherapy 80mg/m2 7 Gynaecology PACLitaxel Monotherapy 80mg/m2 7 227 Gastrointestinal FOLFIRI -14 01/02/2017 372 Nindetanib 382 Gastrointestinal Trifluridine and Tipiracil (Lonsurf ) 18/01/2017 217 Breast Lapatinib and Capecitabine 11/01/2017 216 Breast Capecitabine Monotherapy Gastrointestinal Capecitabine Monotherapy 217 Breast Lapatinib and Capecitabine 237 Skin/Melanoma Dabrafenib Monotherapy 242 Head & Neck Vandetanib Monotherapy 05/01/2017 291 Myeloma Idelalisib Monotherapy 389 Leukaemia/BMT Idelalisib and rituximab 390 Leukaemia/BMT Idelalisib and Ofatumumab 20/12/2016 302 Leukaemia/BMT Ponatinib 340 Ceritinib Monotherapy 384 Gastrointestinal Gemcitabine + Capecitabine 386 Gastrointestinal DOXOrubicin (60mg/m2) 387 Head & Neck CISplatin (100mg/m2) with Radiotherapy (RT) 388 Oral Etoposide
20/12/2016 391 Sarcoma DOXOrubicin (60) and Ifosfamide 392 Sarcoma DOXOrubicin (75) and Ifosfamide 15/12/2016 257 Genitourinary Radium 223 01/12/2016 348 Breast CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide -Triple Negative Breast Cancer 377 Breast Cylophosphamide (Oral) Methotrexate and 5- Fluorouracil (CMF) 378 Breast Cylophosphamide (IV) Methotrexate and 5- Fluorouracil (CMF) 28 Day 381 Breast Cylophosphamide (IV) Methotrexate and 5- Fluorouracil (CMF) 21 Day 16/11/2016 254 Breast Anastrozole Monotherapy 11/11/2016 290 Myeloma ABVD 361 Breast Fulvestrant 371 Breast Letrozole Monotherapy 374 Sarcoma Trabectedin Monotherapy 375 Gynaecology Trabectedin and Pegylated Liposomal DOXOrubicin(PLD) 376 Breast Exemestane Monotherapy 380 Gastrointestinal epirubicin, CISplatin and Capecitabine (ECX) 01/11/2016 235 Gastrointestinal CISplatin and Teysuno-28 cycle 23/10/2016 328 Gastrointestinal FOLFIRI + Cetuximab 21/10/2016 104 Genitourinary Axitinib Monotherapy 253 Breast Tamoxifen Monotherapy 16/09/2016 245 Myeloma Pomalidomide and Dexamethasone 08/08/2016 274 Myeloma Bortezomib + Dexamethasone +Thalidomide (VTD)Induction 275 Myeloma Bortezomib, Melphalan and Prednisolone 299 Myeloma Modified CyBorD/ Bortezomib, Cylophosphamide and Dexamethasone Weekly 30/06/2016 204 Breast Pertuzumab + Trastuzumab + DOCEtaxel 233 Leukaemia/BMT Enzalutamide Monotherapy 27/06/2016 234 Leukaemia/BMT Brentuximab vedotin Monotherapy Myeloma Brentuximab vedotin Monotherapy 20/06/2016 205 Breast Pegylated Liposomal DOXOrubicin (CAELYX) 28 s Gynaecology Pegylated Liposomal DOXOrubicin (CAELYX)
20/06/2016 264 Gynaecology Etoposide CISplatin/Etoposide Methotrexate Actinomycin D (EP/EMA) 316 Breast Dose Dense DOXOrubicin, Cyclophosphamide followed by PACLitaxel (14 s) and Trastuzumab 330 Gastrointestinal Cetuximab (7 s) and Irinotecan (14 s) 331 Gastrointestinal Cetuximab (14 s) and Irinotecan (14 s) 332 Head & Neck CARBOplatin AUC (1.5) Chemoradiation - 7 s 334 Neuro-oncology Temozolomide with RT and Adjuvant 335 Sarcoma Imatinib Therpay-GIST 337 Genitourinary CISplatin, Methotrexate and Vinblastine 342 Neuro-oncology Temozolomide Recurrent 343 Vinorelbine and CISplatin -28 s 376 Breast Exemestane Monotherapy 09/06/2016 347 Skin/Melanoma Pembrolizumab 08/06/2016 105 Skin/Melanoma Ipilimumab Monotherapy 03/06/2016 318 Pemetrexed and CARBOplatin 321 Gastrointestinal Capecitabine/Oxaliplatin (XELOX) 325 Genitourinary Sunitinib 50mg Sarcoma Sunitnib 50mg 326 Genitourinary Temsirolimus Monotherapy 327 Neuroendocrine Sunitnib 37.5mg 329 Gastrointestinal FOLFIRINOX 03/05/2016 224 Leukaemia/BMT Bosutinib Monotherapy 229 Leukaemia/BMT Ruxolitinib Monotherapy 232 Leukaemia/BMT Intravenous Vinorelbine Intravenous Vinorelbine Monotherapy-7s 294 Gastrointestinal Sorafenib Genitourinary Sorafenib Head & Neck Sorafenib 313 Genitourinary DOCEtaxel Monotheray 50mg/m2 Monotherapy- 14 314 Head & Neck CISplatin/5-FU 315 Head & Neck Neoadjuvant DOCEtaxel/CISplatin/5-FU + Chemoradiation + Surgery 317 Pemetrexed and CISplatin 319 CARBOplatin + Oral Etoposide 320 Genitourinary Everolimus Monotherapy Neuroendocrine Everolimus Monotherapy 322 Breast Everolimus and Exemestane 323 Head & Neck DOCEtaxel/CISplatin/5-FU + Chemoradiation 324 Head & Neck DOCEtaxel/CISplatin/5-FU + Radiotherapy
15/04/2016 103 Genitourinary Abiraterone and Prednisolone 238 Gastrointestinal Aflibercept-14 s 08/04/2016 213 Gastrointestinal Irinotecan Monotherapy - 21 s 220 Gefitinib Monotherapy 222 Pemetrexed Monotherapy 230 Breast Nab-PACLitaxel (Abraxane) Monotherapy-21 cycle 303 Gynaecology CARBOplatin (AUC5-7.5) and PACLitaxel 175mg/m2 304 CARBOplatin (AUC6) and PACLitaxel 200mg/m2 308 Gynaecology CARBOplatin (AUC 5-6) and Weekly PACLitaxel 80mg/m2 309 Weekly CARBOplatin and PACLitaxel with Radiotherapy 311 Gynaecology Topotecan Monotherapy-5 Topotecan Monotherapy-5 312 Gynaecology Topotecan Monotherapy-Weekly